Determining the mechanisms underlying augmented renal drug clearance in the critically ill: Use of exogenous marker compounds

Critical Care

Volumn 18, Issue 6, 2014, Pages

  Udy, Andrew A ^a,b   Jarrett, Paul ^c   Stuart, Janine ^c   Lassig Smith, Melissa ^c   Starr, Therese ^c   Dunlop, Rachel ^c   Wallis, Steven C ^b   Roberts, Jason A ^b,c   Lipman, Jeffrey ^b,c  

^a Department of Intensive Care and Hyperbaric Medicine The Alfred ^*  (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; CREATININE; FLUCONAZOLE; FRUCTAN; PINDOLOL; BIOLOGICAL MARKER; OLIGOSACCHARIDE; SINISTRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; KIDNEY TUBULE FUNCTION; LENGTH OF STAY; MALE; OBSERVATIONAL STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; URINARY EXCRETION; URINE VOLUME; BLOOD; CRITICAL ILLNESS; DRUG EFFECTS; KIDNEY FUNCTION TEST; METABOLIC CLEARANCE RATE; PHYSIOLOGY; PROCEDURES; URINE;

ADULT; BIOMARKERS; CREATININE; CRITICAL ILLNESS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; OLIGOSACCHARIDES; PROSPECTIVE STUDIES;

EID: 84927721954     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0657-z     Document Type: Article

References (47)

1. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010, 49:1-16. 10.2165/11318140-000000000-00000, 20000886.
2. Conil JM, Georges B, Mimoz O, Dieye E, Ruiz S, Cougot P, Samii K, Houin G, Saivin S. Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med 2006, 32:2063-2066. 10.1007/s00134-006-0421-1, 17061021.
3. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012, 142:30-39. 10.1378/chest.11-1671, 22194591.
4. Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 2013, 28:695-700. 10.1016/j.jcrc.2013.03.003, 23683557.
5. Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents 2012, 39:420-423. 10.1016/j.ijantimicag.2011.12.011, 22386742.
6. Udy A, Roberts JA, Boots RJ, Lipman J. You only find what you look for: the importance of high creatinine clearance in the critically ill. Anaesth Intensive Care 2009, 37:11-13. 19157339.
7. Lipman J, Udy AA, Roberts JA. Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care 2011, 39:999-1000. 22165348.
8. Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ. Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet 2003, 42:1193-1211. 10.2165/00003088-200342140-00002, 14606929.
9. Gross AS, McLachlan AJ, Minns I, Beal JB, Tett SE. Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. Br J Clin Pharmacol 2001, 51:547-555. 10.1046/j.1365-2125.2001.01390.x, 11422014.
10. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
11. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. AAcute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212. 10.1186/cc2872, 15312219.
12. Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Doogue MP, Jose MD, Langham RG, Lawton PD, McTaggart SJ, Peake MJ, Polkinghorne K, Usherwood T. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust 2012, 197:224-225.
13. Buclin T, Pechère-Bertschi A, Séchaud R, Décosterd LA, Munafo A, Burnier M, Biollaz J. Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method. J Clin Pharmacol 1997, 37:679-692. 10.1002/j.1552-4604.1997.tb04355.x, 9378840.
14. Hsyu PH, Giacomini KM. Stereoselective renal clearance of pindolol in humans. J Clin Invest 1985, 76:1720-1726. 10.1172/JCI112161, 4056049.
15. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E, Decruyenaere J, Depuydt P, Lipman J, Wallis SC, De Waele JJ. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. Crit Care 2013, 17:R84. 10.1186/cc12705, 23642005.
16. Buclin T, Sechaud R, Bertschi AP, Decosterd LA, Belaz N, Appenzeller M, Burnier M, Biollaz J. Estimation of glomerular filtration rate by sinistrin clearance using various approaches. Ren Fail 1998, 20:267-276. 10.3109/08860229809045111, 9574452.
17. Estelberger W, Petek W, Zitta S, Mauric A, Horn S, Holzer H, Pogglitsch H. Determination of the glomerular filtration rate by identification of sinistrin kinetics. Eur J Clin Chem Clin Biochem 1995, 33:201-209. 7626692.
18. Prescott LF, Freestone S, McAuslane JA. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function. Br J Clin Pharmacol 1993, 35:20-29. 8448064.
19. Dowling TC, Frye RF, Fraley DS, Matzke GR. Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. Kidney Int 2001, 59:295-303. 10.1046/j.1523-1755.2001.00491.x, 11135083.
20. Cole BR, Giangiacomo J, Ingelfinger JR, Robson AM. Measurement of renal function without urine collection-a critical evaluation of the constant-infusion technic for determination of inulin and para-aminohippurate. N Engl J Med 1972, 287:1109-1114. 10.1056/NEJM197211302872202, 5082190.
21. Sinnollareddy M, Peake SL, Roberts MS, Playford EG, Lipman J, Roberts JA. Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opin Drug Metab Toxicol 2011, 7:1431-1440. 10.1517/17425255.2011.615309, 21883033.
22. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990, 29:221-226. 10.1111/j.1365-2125.1990.tb03623.x, 2306414.
23. Ujhelyi MR, Bottorff MB, Schur M, Roll K, Zhang H, Stewart J, Markel ML. Urine acidification affects the activity of the organic base transporter in a nonstereoselective manner. J Pharmacol Exp Ther 1996, 276:683-689. 8632337.
24. Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther 1992, 51:379-387. 10.1038/clpt.1992.37, 1563208.
25. Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, Sugiyama Y. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 2012, 340:393-403. 10.1124/jpet.111.184986, 22072731.
26. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem 2013, 56:781-795. 10.1021/jm301302s, 23241029.
27. McLachlan AJ, Gross AS, Beal JL, Minns I, Tett SE. Analytical validation for a series of marker compounds used to assess renal drug elimination processes. Ther Drug Monit 2001, 23:39-46. 10.1097/00007691-200102000-00008, 11206041.
28. Wainer E, Boner G, Rosenfeld JB. Effects of pindolol on renal function. Clin Pharmacol Ther 1980, 28:575-580. 10.1038/clpt.1980.205, 7002425.
29. Lee LJ, Smith DE. Renal excretion and metabolism of p-aminohippurate in the isolated perfused rat kidney. Pharm Res 1988, 5:745-747. 10.1023/A:1015924331585, 3247282.
30. Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med 2001, 27:115-121. 10.1007/s001340000771, 11280621.
31. Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J. Augmented creatinine clearance in traumatic brain injury. Anesth Analg 2010, 111:1505-1510. 10.1213/ANE.0b013e3181f7107d, 21048095.
32. Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, Boots RJ, Lipman J. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically Ill patients with normal plasma creatinine concentrations. Crit Care Med 2014, 42:520-527. 10.1097/CCM.0000000000000029, 24201175.
33. Minville V, Asehnoune K, Ruiz S, Breden A, Georges B, Seguin T, Tack I, Jaafar A, Saivin S, Fourcade O, Samii K, Conil JM. Increased creatinine clearance in polytrauma patients with normal serum creatinine: a retrospective observational study. Crit Care 2011, 15:R49. 10.1186/cc10013, 21291554.
34. Conil JM, Georges B, Fourcade O, Seguin T, Lavit M, Samii K, Houin G, Tack I, Saivin S. Assessment of renal function in clinical practice at the bedside of burn patients. Br J Clin Pharmacol 2007, 63:583-594. 10.1111/j.1365-2125.2006.02807.x, 17166188.
35. Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care 2013, 17:R35. 10.1186/cc12544, 23448570.
36. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: Look before you leap!. Clin Infect Dis 2010, 51:S103-S110. 10.1086/653057, 20597657.
37. Lautrette A, Phan TN, Ouchchane L, Aithssain A, Tixier V, Heng AE, Souweine B. High creatinine clearance in critically ill patients with community-acquired acute infectious meningitis. BMC Nephrol 2012, 13:124. 10.1186/1471-2369-13-124, 23013403.
38. Brown R, Babcock R, Talbert J, Gruenberg J, Czurak C, Campbell M. Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance. Crit Care Med 1980, 8:68-72. 10.1097/00003246-198002000-00004, 7353390.
39. Fuster-Lluch O, Gerónimo-Pardo M, Peyró-García R, Lizán-García M. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008, 36:674-680. 18853585.
40. Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med 2013, 39:1247-1252. 10.1007/s00134-013-2909-9, 23604132.
41. Thomas DM, Coles GA, Williams JD. What does the renal reserve mean?. Kidney Int 1994, 45:411-416. 10.1038/ki.1994.53, 8164427.
42. Udy AA, Morton FJ, Nguyen-Pham S, Jarrett P, Lassig-Smith M, Stuart J, Dunlop R, Starr T, Boots RJ, Lipman J. A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations. BMC Nephrol 2013, 14:250. 10.1186/1471-2369-14-250, 24225349.
43. Bragadottir G, Redfors B, Ricksten SE. Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury - true GFR versus urinary creatinine clearance and estimating equations. Crit Care 2013, 17:R108. 10.1186/cc12777, 23767877.
44. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 1995, 36:395-401. 10.1093/jac/36.2.395, 8522469.
45. Meier J, Nuesch E. Pindolol, a β-adrenoceptor blocking agent with a negligible first-pass effect. Br J Clin Pharmacol 1977, 4:371-372. 10.1111/j.1365-2125.1977.tb00726.x, 901706.
46. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997, 33:52-77. 10.2165/00003088-199733010-00005, 9250423.
47. Hirata-Dulas CA, Awni WM, Matzke GR, Halstenson CE, Guay DR. Evaluation of two intravenous single-bolus methods for measuring effective renal plasma flow. Am J Kidney Dis 1994, 23:374-381. 10.1016/S0272-6386(12)80999-1, 8128938.